{"filing":{"accession_number":"0001493152-26-042196","cik":"0000946644","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-03","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226042196/form8-k.htm"},"events":[{"id":32712,"run_id":30074,"accession_number":"0001493152-26-042196","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses conversion of approximately $450,000 of debt into 1,921,441 shares of common stock at an average conversion price of $0.234 per share. Item 3.02 explicitly addresses \"Unregistered Sales of Equity Securities\" and notes the shares were issued pursuant to Section 3(a)(9) exemption. This is a dilutive equity issuance that increases share count materially and would affect investor assessment of ownership dilution and capital structure.","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":35956,"accession_number":"0001493152-26-042196","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses conversion of approximately $450,000 of debt into 1,921,441 shares of common stock at an average conversion price of $0.234 per share. Item 3.02 explicitly addresses \"Unregistered Sales of Equity Securities\" and notes the shares were issued pursuant to Section 3(a)(9) exemption. This is a dilutive equity issuance that increases share count materially and would affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:37:52.738227+00:00","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-09-10"}]}